Log In
Print
BCIQ
Print
Print this Print this
 

mifamurtide (L-MTP-PE, Mepact) (formerly Junovan)

Also known as: MTP-PE

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionMuramyl tripeptide phosphatidylethanolamine
Molecular Target Caspase recruitment domain family member 15 (CARD15) (NOD2)
Mechanism of ActionImmune modulation
Therapeutic ModalityBiologic
Latest Stage of DevelopmentMarketed
Standard IndicationBone cancer
Indication DetailsTreat high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection in combination with postoperative multi-agent chemotherapy; Treat lung metastases from progression of osteosarcoma; Treat newly diagnosed, resectable non-metastatic osteosarcoma; Treat non-metastatic resectable osteosarcoma; Treat osteosarcoma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$66.7M

$66.7M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today